Special Issue

Artificial Intelligence in Cancer Screening

Message from the Guest Editors

Artificial intelligence (AI) is a powerful class of methods for decision support, having rapidly evolved over recent years. Several approaches have been developed to analyze the increasingly extensive and variably complex datasets often publicly available. With enthusiasm. Al is beginning to be applied to several facets of screening intervention, from the risk stratification of subjects to be invited, to the reading of radiological, optical, and histocytopathological images, and integration with stool, serum, and fluid biomarkers to ultimately promote and reinforce the implementation of screening in public health services, thanks to an improved cost/benefit ratio. In this Special Issue of Cancers, we offer an overview of the current and potential applications of Al to the screening interventions considering, on the one hand, the AI methodological and technical developments and, on the other hand, the applications to specific screening contexts.

- artificial intelligence
- biomarkers
- breast cancer
- cancer screening
- cervical cancer
- colorectal cancer
- deep learning
- lung cancer
- machine learning
- risk stratification

Guest Editors

Prof. Dr. Mario Mascalchi

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50121 Florence, Italy

Dr. Stefano Diciotti

Department of Electrical, Electronic, and Information Engineering "Guglielmo Marconi"—DEI, University of Bologna, Bologna, Italy

Deadline for manuscript submissions

closed (31 October 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/122162

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

